SHShiyu Hu

Shiyu Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shiyu Hu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The contributions of active and passive smoking to COPD-related mortality and DALYs in the context of COVID-19: Global Burden 2019–2021

    by Shiyu Hu, Xiaoli Tan, Danying Zhang, Ye Zhang, Xiaodong Lv, Wenyu Chen

    Chronic obstructive pulmonary disease (COPD) is a major global health issue with high morbidity and mortality. While assessing the overall burden of COPD, it is essential to further quantify the contributions of active and passive smoking to COPD-related mortality and DALYs. By utilizing COPD data from the 2021 Global Burden of Disease study, we analyzed the age-standardized incidence (ASIR), prevalence (ASPR), mortality (ASMR) and disability-adjusted life years (ASDR) rates (per 100000), and the risk factors associated with mortality due to COPD. Additionally, we calculated the estimated annual percentage changes (EAPCs) during the study period. In 2021, global COPD incidence, prevalence, deaths and disability-adjusted life years (DALYs), increased compared to those in 2019, reaching 16.9 million (95% UI: 15.5–18.3 million), 213 million (95% UI: 195.0–234.0 million), 3.7 million (95% UI: 3.3–4.1), and 79.8 million (95% UI: 74.0–86.0), respectively. The ASPR, ASMR and ASDR declined to 2512.9 (95% UI: 2293.9–2748.5), 45.2 (95% UI: 40.6–49.7), and 940.7 (95% UI: 871.5–1014.6), respectively, while the ASIR slightly increased compared to 2019. In 2021, tobacco use caused 1510389 deaths and 31613440 DALYS from COPD worldwide (ASMR: 18; ASDR: 370). Smoking accounted for 1334961 COPD deaths and 27794778 COPD DALYs (ASMR: 16; ASDR: 326), while secondhand smoke exposure resulted in 266125 COPD deaths and 5662905 COPD DALYs (ASMR: 3; ASDR: 67). COPD remains a global challenge. The outbreak of COVID-19 does not appear to have altered the trend of COPD disease burden changes but continued monitoring and adaptive management are essential. Meanwhile, in the context of the COVID-19 pandemic, smoking and tobacco exposure remain important risk factors contributing to the burden of COPD, underscoring the urgent need for heightened attention from the public and relevant authorities.

  • Open Access

    Accuracy of Radiomics-Based Machine Learning for Predicting Risk of Recurrence in Non–Small Cell Lung Cancer: Systematic Review and Meta-Analysis

    by Junpei Wu, Ye Zhang, Jiaye Wang, Chengshui Chen, Shiyu Hu, Wenyu Chen

    Background: During the diagnosis and treatment of non–small cell lung cancer (NSCLC), detecting the risk of its recurrence in an early phase is still challenging. Recent studies have investigated the radiomics-based machine learning (ML) models for detecting the risk of recurrence in NSCLC. However, there is still insufficient systematic evidence to prove its efficiency. Objective: This study is designed to systematically evaluate the effectiveness of radiomics-based ML in predicting the risk of recurrence in NSCLC, aiming to provide evidence-based support for the subsequent development of scoring tools to forecast recurrence risk. Methods: For acquiring research on radiomics-based models for forecasting the risk of recurrence in NSCLC, Cochrane Library, Web of Science, PubMed, and Embase were systematically retrieved, up to October 24, 2025. Studies on analyzing the recurrence of NSCLC using radiomics-based ML were included, while those in which only texture analysis was conducted or radiomics-based ML was not constructed were excluded. The Radiomics Quality Score (RQS) was used to appraise the eligible studies. Subgroup analyses were conducted according to the variables of the model, the background of treatment, the stage of lung cancer, and the pathological type. Results: Ultimately, 30 eligible studies in total were included, covering 7964 patients with NSCLC. According to the meta-analysis, the c-index of radiomics-based ML models for forecasting the risk of recurrence in NSCLC was 0.850 (95% CI 0.834‐0.866, 95% prediction interval [PI] 0.623‐1.004) in the training set. Specifically, the pooled c-index was 0.876 (95% CI 0.853‐0.900) among the patients receiving the stereotactic body radiation therapy and 0.825 (95% CI 0.804‐0.848) among those who received surgeries combined with other adjuvant treatment regimens. The c-index of the radiomics-based ML models combined with clinical features for forecasting the risk of recurrence in NSCLC was 0.833 (95% CI 0.822‐0.854, 95% PI 0.717‐0.945) in the training set. In contrast, the c-index of radiomics-based ML models for forecasting the risk of recurrence in NSCLC was 0.878 (95% CI 0.854‐0.902, 95% PI 0.681‐1.000) in the validation set. The c-index of radiomics-based ML models combined with clinical features for forecasting the risk of recurrence in NSCLC was 0.854 (95% CI 0.830‐0.878, 95% PI 0.655‐0.992) in the validation set. The average RQS across the included studies was 27.4%, revealing methodological limitations and an absence of standardization. Conclusions: This study is the first to confirm that radiomics-based ML models effectively predict the risk of recurrence in NSCLC. This study provides evidence-based support for the subsequent development or updating of radiomics-based ML models. However, the current methodological application of radiomics remains concerning. Therefore, in the future, research should standardize the workflow for implementing radiomics-based ML and incorporate multicenter imaging data to enhance its generalizability.


  • Open Access

    Association Between C-Reactive Protein-Triglyceride Glucose Index and All-Cause Mortality and Exacerbation in Adult Asthma: NHANES, 1999–2010 and 2015–2018

    by Jiaye Wang, Miaomiao Zhao, Hao Chen, Shiyu Hu, Chengshui Chen, Yingqing Zhang, Wenyu Chen

    Wang J, et al. Allergy Asthma Immunol Res. 2026 Sep;18(5):721-737. https://doi.org/10.4168/aair.2026.18.5.721